Actinium Pharmaceuticals (NYSE:ATNM) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a research note issued to investors on Monday,Benzinga reports. The firm currently has a $4.00 price target on the stock.

Separately, StockNews.com upgraded shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, April 18th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.40.

Actinium Pharmaceuticals Trading Down 0.8 %

Shares of ATNM opened at $1.30 on Monday. The firm’s 50-day moving average is $1.29 and its two-hundred day moving average is $1.37. Actinium Pharmaceuticals has a twelve month low of $1.03 and a twelve month high of $10.24. The firm has a market capitalization of $40.55 million, a P/E ratio of -0.94 and a beta of -0.27.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Vontobel Holding Ltd. acquired a new position in shares of Actinium Pharmaceuticals in the fourth quarter worth $32,000. Barclays PLC raised its holdings in shares of Actinium Pharmaceuticals by 323.0% in the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after acquiring an additional 32,784 shares during the last quarter. Sei Investments Co. acquired a new position in shares of Actinium Pharmaceuticals in the fourth quarter worth $62,000. Bank of America Corp DE raised its holdings in shares of Actinium Pharmaceuticals by 76.6% in the fourth quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after acquiring an additional 34,176 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV raised its holdings in shares of Actinium Pharmaceuticals by 42.7% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 91,007 shares of the company’s stock worth $115,000 after acquiring an additional 27,222 shares during the last quarter. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).